CASI Pharmaceuticals Inc (NASDAQ:CASI), weekly performance is 3.45%. On last trading day company shares ended up $1.80. Analysts mean target price for the company is $1.00. CASI Pharmaceuticals Inc (NASDAQ:CASI), distance from 50-day simple moving average (SMA50) is -0.38%.
Veracyte Inc (NASDAQ:VCYT), CEO Bonnie H. Anderson unloaded 4,000 shares of Veracyte stock on the open market in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $16.45, for a total value of $65,800.00. Veracyte Inc (NASDAQ:VCYT), fell 0.30% in last trading session and ended the day on $16.77. VCYT, Gross Margin is 46.40% and its return on assets is -50.10%. Veracyte Inc (NASDAQ:VCYT), quarterly performance is 2.19%.
On June 17, 2014, Alcobra Ltd (NASDAQ:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the JMP Securities Healthcare Conference, taking place June 24-25 in New York City. Alcobra Ltd (NASDAQ:ADHD), shares moved down 4.89% in last trading session and was closed at $17.51, while trading in range of $17.27 – 18.99. Alcobra Ltd (NASDAQ:ADHD), year to date (YTD) performance is -2.72%.
On June 19, 2014, Mast Therapeutics Inc (NYSEMKT:MSTX), announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors. Dr. Dittrich, a cardiologist by training, has more than 20 years of experience in cardiac therapeutic research and clinical development. Mast Therapeutics Inc (NYSEMKT:MSTX), ended the last trading day at $0.685. Company weekly volatility is calculated as 6.12% and price to cash ratio as 1.58. Mast Therapeutics Inc (NYSEMKT:MSTX), showed a negative weekly performance of 7.03%.
Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares are being offered by Actinium. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), weekly performance is -20.81%. On last trading day company shares ended up $8.75. Analysts mean target price for the company is $18.00. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), distance from 50-day simple moving average (SMA50) is -22.34%.